RWS Integrates eCOA Services to Cut Clinical Trial Delays
Event summary
- RWS launched a new linguistic validation service on July 14, 2026, combining COA licensing, translation, eCOA migration, and rater training under one program team.
- The service aims to reduce delays in global clinical trials by streamlining workflows and consolidating accountability.
- RWS expanded its digital health portfolio to include rater training as part of this transformation.
- The company is investing in AI-powered tools to automate repetitive tasks and strengthen quality oversight.
The big picture
RWS's move addresses a longstanding inefficiency in clinical trials: fragmented service delivery across multiple vendors. By consolidating eCOA services under one program team, the company aims to reduce operational and regulatory risks while speeding up global study execution. This aligns with broader industry trends toward streamlined, tech-enabled solutions in clinical research.
What we're watching
- Adoption Pace
- How quickly pharmaceutical companies and CROs will adopt RWS's integrated service model to accelerate clinical trial timelines.
- AI Impact
- Whether AI-powered automation can maintain scientific rigor while significantly reducing delivery times in linguistic validation.
- Competitive Response
- The pace at which competitors will introduce similar integrated service models to challenge RWS's market position.